Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Human Genome Epidemiology Literature Finder|Home|PHGKB

Human Genome Epidemiology Literature Finder


Last data update: Dec 10, 2023. (Total: 223917Documents)
   dataset        GWAS Only
Filtered By:

Previous    

Records 1 - 5 (of 5 Records)

Query Trace: Appetite and PIK3CA[original query]
Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.
Cancer discovery 2017 Mar .
Juric Dejan, Krop Ian, Ramanathan Ramesh K, Wilson Timothy R, Ware Joseph A, Sanabria Bohorquez Sandra, Savage Heidi, Sampath Deepak, Salphati Laurent, Lin Ray, Jin Huan, Parmar Hema, Hsu Jerry Y, Von Hoff Daniel D, Baselga Jo
A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors.
Investigational new drugs 2018 Apr .
Aghajanian Carol, Bell-McGuinn Katherine M, Burris Howard A, Siu Lillian L, Stayner Lee-Ann, Wheler Jennifer J, Hong David S, Kurkjian Carla, Pant Shubham, Santiago-Walker Ademi, Gauvin Jennifer L, Antal Joyce M, Opalinska Joanna B, Morris Shannon R, Infante Jeffrey
Phosphatidylinositol 3-Kinase ?-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018 2 36 (13): 1291-1299.
Juric Dejan, Rodon Jordi, Tabernero Josep, Janku Filip, Burris Howard A, Schellens Jan H M, Middleton Mark R, Berlin Jordan, Schuler Martin, Gil-Martin Marta, Rugo Hope S, Seggewiss-Bernhardt Ruth, Huang Alan, Bootle Douglas, Demanse David, Blumenstein Lars, Coughlin Christina, Quadt Cornelia, Baselga Jo
Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer.
The oncologist 2020 12 26 (4): 290-e545.
van Brummelen Emilie M J, Huijberts Sanne, van Herpen Carla, Desar Ingrid, Opdam Frans, van Geel Robin, Marchetti Serena, Steeghs Neeltje, Monkhorst Kim, Thijssen Bas, Rosing Hilde, Huitema Alwin, Beijnen Jos, Bernards Rene, Schellens J
FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2020 11 27 (7): 1842-1849.
Narayan Preeti, Prowell Tatiana M, Gao Jennifer J, Fernandes Laura L, Li Emily, Jiang Xiling, Qiu Junshan, Fan Jianghong, Song Pengfei, Yu Jingyu, Zhang Xinyuan, King-Kallimanis Bellinda L, Chen Wei, Ricks Tiffany K, Gong Yutao, Wang Xing, Windsor Katherine, Rhieu Steve Y, Geiser Gerlie, Banerjee Anamitro, Chen Xiaohong, Reyes Turcu Francisca, Chatterjee Deb K, Pathak Anand, Seidman Jeffrey, Ghosh Soma, Philip Reena, Goldberg Kirsten B, Kluetz Paul G, Tang Shenghui, Amiri-Kordestani Laleh, Theoret Marc R, Pazdur Richard, Beaver Julia
TOP